NDATRANSDERMALSYSTEM
Approved
Mar 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Mechanism of Action
Pharmacologic Class:
Central Nervous System Stimulant
Clinical Trials (1)
A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine
Started Oct 2019
430,000 enrolled
Attention Deficit Disorder With Hyperactivity
Loss of Exclusivity
LOE Date
Jan 6, 2042
192 months away
Patent Expiry
Jan 6, 2042